Complex skin defects, such as burns and acute cutaneous trauma, are life-threatening injuries, often requiring temporary allograft placement to maintain fluid homeostasis and prevent infection until permanent wound closure is possible.
The Problem:
The current standard of care for the management of full-thickness wounds that are unable to be closed in a single surgical stage is temporary coverage with cadaver allograft until an acceptable wound bed has been established. This approach has limitations including limited availability of human cadaver skin, the risk of disease transmission from cadaveric grafts, and inconsistent cadaver allograft quality.
Basic/Clinical Science:
Near-diploid neonatal human keratinocyte cell line (NIKS)-based human skin tissue is a full-thickness, living human skin substitute composed of a dermal analog containing normal human dermal fibroblasts and a fully-stratified, biologically and metabolically active epidermis generated from NIKS keratinocytes, a consistent and unlimited source of pathogen-free human epidermal progenitor cells.
Clinical Care Relevance:
NIKS-based human skin tissue is a living bioengineered skin substitute (BSS) intended to provide immediate wound coverage and promote wound healing through sustained expression by living cells of wound healing factors.
Conclusion:
A phase I/IIa clinical trial found that NIKS-based BSS was well tolerated and comparable to cadaver allograft in the ability to prepare full-thickness complex skin defects prior to autografting. There were no deaths and no adverse events (AE) associated with this BSS. Exposure of the study subjects to the skin substitute tissue did not elicit detectable immune responses. Notably, this tissue remained viable and adherent in the wound bed for at least 7 days.
Get full access to this article
View all access options for this article.
References
1.
KaganRJ, PeckMD, AhrenholzDH, HickersonWL, HolmesJH, KorentagerRAet al.American Burn Association White Paper: Surgical Management of the Burn Wound and Use of Skin Substitutes. American Burn Association, 2009; 1–44.
2.
HanA, ZenilmanJ, MelendezJ, ShirtliffM, AgostinhoA, JamesGet al.The importance of a multifaceted approach to characterizing the microbial flora of chronic wounds. Wound Repair and Regen, 2011; 19:532.
3.
LazarusG. Wound microbiology: tabula rosa, a blank slate. Wound Repair and Regen, 2011; 19:531.
4.
DziewulskiP, BarretJP. Assessment, operative planning and surgery for burn wound closure. Burn Care. WolfSE, HerndonDE. Austin, TX: Landes Bioscience, 1999; 19–52.
5.
PhamTN, GibranNS, HeimbachDM. Evaluation of the burn wound: management decisions. Total Burn Care. HerndonDN. Galveston, TX: Saunders, 2007; 119–126.
HansbroughJF, FrancoES. Skin replacements. Clinics in Plastic Surgery, 1998; 25:407.
8.
SchurrMJ, FosterKN, CentanniJM, ComerAR, WicksA, GibsonALet al.Phase I/II clinical evaluation of StrataGraft: a consistent, pathogen-free human skin substitute. J Trauma-Injury Infect Crit Care, 2009; 66:866.
9.
CentanniJM, StraseskiJA, WicksA, HankJA, RasmussenCA, LokutaMAet al.StrataGraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds. Annals of Surgery, 2011; 253:672.
10.
Allen-HoffmannBL, SchlosserSJ, IvarieCA, SattlerCA, MeisnerLF, O'ConnorSL. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J Invest Dermatol, 2000; 114:444.
11.
BrighamPA, McLoughlinE. Burn incidence and medical care use in the United States: estimates, trends, and data sources. J Burn Care Rehabil, 1996; 17:95.
12.
Mass casualties: burns. Centers for Disease Control and Prevention. www.bt.cdc.gov/masscasualties/burns.asp
13.
KauvarDS, WolfSE, WadeCE, CancioLC, RenzEM, HolcombJB. Burns sustained in combat explosions in Operations Iraqi and Enduring Freedom (OIF/OEF explosion burns)Burns, 2006; 32:853.
14.
CancioLC, HorvathEE, BarilloDJ, KopchinskiBJ, CharterKR, MontalvoAEet al.Burn support for Operation Iraqi Freedom and related operations, 2003 to 2004. J Burn Care Rehabil, 2005; 26:151.
15.
BoyceST, KaganRJ, MeyerNA, YakuboffKP, WardenGD. The 1999 clinical research award. Cultured skin substitutes combined with Integra Artificial Skin to replace native skin autograft and allograft for the closure of excised full-thickness burns. J Burn Care Rehabil, 1999; 20:453.
16.
SvensjoT, PomahacB, YaoF, SlamaJ, ErikssonE. Accelerated healing of full-thickness skin wounds in a wet environment. Plast Reconstr Surg, 2000; 106:602discussion 613–614.
17.
AtiyehBS, El-MusaKA, DhamR. Scar quality and physiologic barrier function restoration after moist and moist-exposed dressings of partial-thickness wounds. Dermatol Surg, 2003; 29:14.
ObengMK, McCauleyRL, BarnettJR, HeggersJP, SheridanK, SchutzlerSS. Cadaveric allograft discards as a result of positive skin cultures. Burns, 2001; 27:267.
20.
EisenbudD, HuangN, LukeS, SilberklangM. Skin substitutes, wound healing: current status and challenges. Wounds, 2004; 16:2.
21.
BoyceST, KaganRJ, GreenhalghDG, WarnerP, YakuboffKP, PalmieriTet al.Cultured skin substitutes reduce requirements for harvesting of skin autograft for closure of excised, full-thickness burns. J Trauma, 2006; 60:821.
22.
GravanteG, Di FedeMC, AracoA, GrimaldiM, De AngelisB, ArpinoAet al.A randomized trial comparing ReCell system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns. Burns, 2007; 33:966.
23.
Food and Drug Administration. Enforcement Report for April 2, 2008: AlloDerm recall.
24.
Food and Drug Administration. Enforcement Report for April 16, 2008: AlloDerm recall.
25.
Food and Drug Administration. Recall of Human Tissue Products-LifeCell Corp September 30, 2005: AlloDerm recall.
26.
MacNeilS. Progress and opportunities for tissue-engineered skin. Nature, 2007; 445:874.
27.
ParenteauNL, BilboP, NolteCJ, MasonVS, RosenbergM. The organotypic culture of human skin keratinocytes and fibroblasts to achieve form and function. Cytotechnology, 1992; 9:163.
28.
GriffithLG, NaughtonG. Tissue engineering: current challenges and expanding opportunities. Science, 2002; 295:1009.
29.
HrabchakC, FlynnL, WoodhouseKA. Biological skin substitutes for wound cover and closure. Expert Review of Medical Devices, 2006; 3:373.
BarnstableCJ, JonesEA, CrumptonMJ. Isolation, structure and genetics of HLA-A, -B, -C and -DRw (Ia) antigens. Br Med Bull, 1978; 34:241.
34.
DaarAS, FuggleSV, FabreJW, TingA, MorrisPJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation, 1984; 38:287.
35.
DaarAS, FuggleSV, FabreJW, TingA, MorrisPJ. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation, 1984; 38:293.
36.
WiknerNE, HuffJC, NorrisDA, BoyceST, CaryM, KissingerMet al.Study of HLA-DR synthesis in cultured human keratinocytes. J Invest Dermatol, 1986; 87:559.
37.
MorhennVB, BenikeCJ, CoxAJ, CharronDJ, EnglemanEG. Cultured human epidermal cells do not synthesize HLA-DR. J Invest Dermatol, 1982; 78:32.
38.
HuS, KirsnerRS, FalangaV, PhillipsT, EaglsteinWH. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. Wound Repair Regen, 2006; 14:427.
39.
PhillipsTJ, ProvanA, ColbertD, EasleyKW. A randomized single-blind controlled study of cultured epidermal allografts in the treatment of split-thickness skin graft donor sites. Arch Dermatol, 1993; 129:879.
40.
GriffithsM, LivingstoneR, PriceR, NavsariaH. Survival of Apligraf in acute human wounds. Tissue Eng, 2004; 10:1180.
41.
PruittBAJr., LevineNS. Characteristics and uses of biologic dressings and skin substitutes. Arch Surg, 1984; 119:312.
42.
EaglsteinWH, IriondoM, LaszloK. A composite skin substitute (graftskin) for surgical wounds. A clinical experience. Dermatol Surg, 1995; 21:839.
43.
TrentJF, KirsnerRS. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent. Int J Clin Pract, 1998; 52:408.
44.
OrTec International I: Summary of Safety and Effectiveness Data for OrCel. 2001.
45.
BrainA, PurkisP, CoatesP, HackettM, NavsariaH, LeighI. Survival of cultured allogeneic keratinocytes transplanted to deep dermal bed assessed with probe specific for Y chromosome. BMJ, 1989; 298:917.
46.
Advanced BioHealing: Dermagraft® Human Fibroblast-Derived Dermal Substitute. 2007.
47.
BoydM, FlaszaM, JohnsonPA, RobertsJS, KempP. Integration and persistence of an investigational human living skin equivalent (ICX-SKN) in human surgical wounds. Regen Med, 2007; 2:363.
48.
WilkinsLM, WatsonSR, ProskySJ, MeunierSF, ParenteauNL. Development of a bilayered living skin construct for clinical applications. Biotechnol Bioeng, 1994; 43:747.
49.
NemecekGM, DayanAD. Safety evaluation of human living skin equivalents. Toxicol Pathol, 1999; 27:101.
50.
MillerAB, HoogstratenB, StaquetM, WinklerA. Reporting results of cancer treatment. Cancer, 1981; 47:207.
51.
GerdesJ, LemkeH, BaischH, WackerHH, SchwabU, SteinH. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 1984; 133:1710.
LaningJC, DeLucaJE, Hardin-YoungJ. Effects of immunoregulatory cytokines on the immunogenic potential of the cellular components of a bilayered living skin equivalent. Tissue Eng, 1999; 5:171.
54.
RasmussenCA, GibsonAL, SchlosserSJ, SchurrMJ, Allen-HoffmannBL. Chimeric composite skin substitutes for delivery of autologous keratinocytes to promote tissue regeneration. Annals of Surgery, 2010; 251:368.
Thomas-VirnigCL, CentanniJM, JohnstonCE, HeLK, SchlosserSJ, Van WinkleKFet al.Inhibition of multidrug-resistant Acinetobacter baumannii by nonviral expression of hCAP-18 in a bioengineered human skin tissue. Mol Ther, 2009; 17:562.
